-
Business focus
Affitech utilizes its unrivalled breadth of expertise in human antibody and target discovery to create therapeutic antibodies for the treatment of cancer, infectious disease, inflammation, and other diseases of unmet medical needs.
Contact
Gaustadalleen 21,
NO-0349 Oslo
Phone: +47 22 95 87 58
FAX: +47 22 95 83 58Contact: CEO Martin Welschof
-
Business focus
Algeta ASA, headquartered in Oslo, Norway, is a public therapeutics company dedicated to the development of novel anticancer therapeutics based on alpha-pharmaceuticals.
Contact
P.O.Box 54 Kjelsås,
NO-0411 Oslo
Phone: +47 23 00 79 90
Fax: +47 23 00 79 91
Contact: CEO Andrew Kay -
Business focus
The company is developing new medications and medical devices based on alginate polysaccharide technologies.
Contact
Industriveien 33,
NO-1337 Sandvika
Phone: +47 94 86 89 75
Fax: +47 67 54 57 70Contact: Rolf Myrvold
-
Business focus
AstraZeneca develops and markets cost effective therapeutic solutions based on innovative medications to give people a better life.
Contact
Visiting address: Hoffsveien 70B,
NO-0377 OSLO
Postal adress: PO Box 200 Vindern,
NO-0319 Oslo
Phone: +47 21 00 64 00
Fax: + 21 00 64 01
Contact: Global Vice President MCCD Henrik Lund -
Business focus
Avexxin is a pharmaceutical company focused on developing and commercializing novel small molecule therapeutics for patients with chronic inflammatory conditions.
Contact
Avvexin AS,
Department of Biology,
Norwegian University of Science and Technology,
NO-7491 Trondheim
Phone: +47 73 59 61 07
Contact: Professor Berit Johansen -
Business focus
Axellia is a leading producer of active pharmaceutical ingredients (APIs), specialised in fermented antibiotics and injectable finished products.
Contact
P.O. Box 158 Skøyen,
NO-0212 Oslo
Phone: +47 22 52 92 46 / 902 08 233
Fax: +47 22 50 58 60Contact: Patent Manager Marianne Nesje
-
Business focus
Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders,infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology tocreate products that advance patient care worldwide.
Contact
Baxter As
Gjerdrums vei 11,
NO-0486 Oslo
Phone:+47 22 58 48 00
Contact: Sverre Slaastad, Country Managing Director
-
Business focus
The aim of Bio-Medisinsk Innovasjon AS is to increase the value of biomedical innovations in an early phase and develop projects to interesting investment objects for venture capital and industry. BMI cooperates with Oslo Innovation Center AS, Medinnova and the technology transfer office at the University of Oslo, Birkeland Innovasjon AS.
Contact
Gaustadalléen 21,
NO-0349 OSLO.
Phone: +47 22 95 81 90 / 93 41 17 14
Fax: +47 22 60 44 27Contact: CEO Ingrid Alfheim
-
Business focus
Development of immunotherapies and vaccines. Peptide based immunotherapies, computer-aided design of therapeutic peptides. Main project: Development of immunotherapy for HIV-infected patients.
Contact
P.O. Box 1823 Gulset,
NO-3703 Skien.
Phone: +47 35 50 57 50
Fax: +47 35 50 57 01Contact: Birger Sørensen
-
Business focus
Bioactive compounds which can modulate the innate immune system and thus prevent and treat diseases in humans and animals, and marine enzymes used in research and diagnostics.Biotec Pharmacon ASA is a biopharmaceutical company that develops new pharmaceutical products for treatment of immune related diseases.
Contact
Strandgt. 3,
NO-9008 Tromsø.
Phone: +47 77 64 89 00
Fax: +47 77 64 89 01Contact: CEO Lars Viksmoen
-
Business focus
Borregaard is a leading supplier of wood based specialty chemicals, a supplier of food and feed ingredients and pharmaceutical intermediates. Borregaard is manufacturing and supplying a wide range of products and chemicals from many plants in Europe, Africa, South-America, Noth-America and Asia. Borregaard's plants in Norway and Switzerland is claimed to be the most advanced biorefineries in operation in the world today. The pharmaceutical intermediate manufacturing equipment is cGMP certified.
Borregaard has since 2007 started development of biochemicals, biofuels, proteins and biomaterials from a wide range of 2nd generation biomasses (that is whithout competition with food production).Contact
P.O. Box 162
NO-1701 Sarpsborg.
Phone: +47 69 11 81 60
Fax: +47 69 11 86 40Contact: Technology Director Business Development, Gudbrand Rødsrud
-
Business focus
Discovery and development of superior pharmaceuticals based on Lipid Vector Technology (LVT). LVT involves the chemical binding of specific fatty acids to pharmaceutical agents, thereby creating new chemical entities with improved biological properties.
Contact
Parkveien 53 B,
NO 0256 Oslo.
Phone: + 47 24 11 09 50
Fax: + 47 24 11 09 51
Contact: CEO Geir Chr Melen -
Business focus
Epitarget AS is a privately owned Norwegian life science company dedicated to developing cancer therapies. In current chemotherapy the whole body is treated, not only the diseased parts. The company focuses on developing technology to deliver approved and established cancer drugs exactly where they are needed by means of ultrasound mediated drug release. The main product is ultrasound sensitive drug carrying particles.
Contact
Pb 7159 Majorstuen,
NO-0307 Oslo.
Phone: +47 23 20 12 95
Fax: +47 23 20 12 49Contact: CEO Esben A. Nilssen
-
Business focus
FMC Biopolymer AS is among the world’s largest alginate manufacturers and offers a full range of functionalities and capabilities to assist formulators in creating and launching innovative alginate based products and systems for pharmaceutical, industrial, and food applications.
Contact
Tomtegt. 36, P.O. Box 494 Brakerøya,
NO-3002 Drammen.
Phone: +47 32 20 35 29 / 415 09 623
Fax: +47 32 20 35 10Contact: Head of Alginate Research: Edvar Onsøyen, Ph.D
-
Business focus
FürstNAT is a privately held laboratory in the Fürst consortium. FürstNAT offers high quality molecular biology diagnostic testing for routine and research use.
Contact
Søren Bullsv. 25
NO-1051 Oslo
Tel: +47 22 90 95 00
Fax: +47 22 90 96 06
Contact: Nils Reinton -
Business focus
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest.
GE Healthcare's broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases and other conditions earlier. Our vision for the future is to enable a new "early health" model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries.Contact
P.O. Box 4220 Nydalen,
NO-0401 Oslo.
Phone:
Fax: +47 23 18 60 00
Contact: Vice President Bjørn Fuglaas -
Business focus
Research-based pharmaceutical and healthcare company.
Contact
Pb. 180 Vinderen,
NO-0319 Oslo.
Phone: +47 22 70 20 51
Fax: +47 22 70 20 03Contact: Medical director Olav Flaten
-
Business focus
HIV therapy based on immune stimulation.
Contact
Gaustadalléen 21,
NO-0349 Oslo.
Phone: +47 22 95 86 98
Fax: +47 22 60 44 27Contact: CEO Birgit Stattin Norinder
-
Business focus
Cancer and infectious diseases: Patented new drug candidates.
Contact
Sykehusveien 21/23,
P.O. Box 6447,
NO- 9294 Tromsø.
Phone: +47 77 67 55 00
Fax: +47 77 67 55 01Contact: CEO Øystein Rekdal
-
Business focus
Nycomed was established in Norway by the pharmacist, Morten Nyegaard in 1874. The headquarter is located in Zürich , Zwitzerland. Nycomed is present in more than 50 countries worldwide and supplies more than 100 markets . The company has 12 000 employees worldwide , and is one of the 25 largest pharmaceutical companies in the world.
Nycomed markets a differentiated portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management . In addition, Nycomed is a supplier of OTC- medicines, vitamins and food supplements to pharmacies in selected markets.
Nycomed acquired Altana in January 2007. The global revenue in 2008 amounted to 3. 3 billion Euro. In Norway, Nycomed has about 470 employees with production sites in Asker and Elverum.
Contact
Postboks 205,
1372 Asker,
Norway,
T +47 6676 3030
General manager: Per S. Thoresen | +47 906 14 620
Communications Director: Brita Sangolt | +47 911 80 646
-
Business focus
Each year, Pfizer pharmaceuticals help over 150 million people throughout the world live longer, healthier lives. With medicines across 11 therapeutic areas, we help to treat and prevent many of the most common, and most challenging, conditions of our time. We also build partnerships to help ensure access to our medicines and educate and empower consumers.
Contact
P.O. Box 3,
NO-1324 Lysaker.
Phone: +47 67 52 61 03
Fax: +47 67 52 61 99Contact: Torfinn Hansen
-
Business focus
Pronova BioPharma is a global leader in the research, development and manufacture of marine-originated omega-3 derived pharmaceutical products. Core activities are founded upon marine-oil extracting and manufacturing traditions dating back to the 1900s.
Contact
P.O. Box 420,
NO-1327 Lysaker.
Phone: +47 22 53 48 50
Fax: +47 22 53 48 51Contact: Gunnar Berge
-
Business focus
Rheumatech AS has identified and patented the gene/protein Cbeta2 and its function. Cbeta2 is expressed (found) in immune cells (leucocyte or T- and B cells) which are crucial in the process of making the body respond optimally against infections and diseases.
Contact
Forskningsveien 2A,
PO Box 180 Vinderen;
NO-0319 Oslo.
Phone: +47 92 88 58 83Contact: Eirik Næss-Ulseth
-
Business focus
Sanofi- aventis is Europe's largest, and one of the world's leading pharmaceutical companies.
The global headquarters is in Paris, and we are 70 employees in Norway. Focused on patients needs, sanofi-aventis offers a range of essential healthcare assets, including a broad-based product portfolio. Our biggest therapeuticall areas are oncology, diabetes, cardiovascular disease and the central nervous system In addition , we are a growing supplier in consumer healthcare and prescription-free medicines.Contact
Strandveien 15
Postboks 133
1366 Lysaker
Phone: +47 67 10 71 00/36
Fax: +47 67 10 71 01Contact: Annelene Svingen
-
Business focus
SantoSolve AS develops novel drugs based on non-radioactive strontium. The company’s lead product is currently in phase III for two different pain indications.
-
Business focus
siRNAsense is a Norwegian biotechnology company, focussing on the first critical steps in developing therapeutics based on RNAi technology.
Contact
Gaustadallèen 21,
NO-0349 Oslo.
Phone: +47 22 95 81 92
Fax: +47 22 60 44 27Contact: R&D director: Dr. Mohammed Amarzguioui
-
Business focus
Smartfish develops advanced nutritional compositions for improving cell functions and treating underlying mechanisms in disease.
Contact
Hoffsveien 65 A,
NO-0377 OsloP.O.Box 77 Smestad,
NO-0309 OsloPhone: +47 22 51 98 80
Fax: +47 22 51 98 81
Contact : Jens Nordahl -
Business focus
Spermatech AS is a pioneer in the development of non-hormonal drugs to regulate sperm motility for the purpose of contraception. Our primary focus is to discover and develop a novel small molecule male anti-fertility agent.
Contact
Forskningsveien 2A,
PO Box 180 Vinderen;
NO-0319 Oslo.
Phone: +47 92 88 58 83
Contact: Eirik Næss-Ulseth -
Business focus
Pharmaceutical company -- specializing in pharmaceuticals and fine chemicals for the world markets.
Contact
P.O. 9113 Grønland,
NO-0133 Oslo.
Phone: +47 22 99 86 00
Fax: +47 22 99 86 01Contact: Director of business development, Halvor Weider
Norwegian Bioindustry Association
Middelthuns gt. 27, Postboks 7072 Majorstuen, NO-0306 Oslo Tel: +47 23 08 88 00 / +47 23 08 88 18 / +47 91 10 54 91 Email: biotek@norskindustri.no Fax: +47 23 08 88 98